Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a class of medicines, which engages intracellular targets that have long been considered inaccessible. Co.'s Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform (EEV Platform), the Co. is building a robust development portfolio of therapeutic candidates. Its first two drug candidates, ENTR-601-44 and VX-670, are in clinical trials. We show 13 historical shares outstanding datapoints in our TRDA shares outstanding history coverage, used to compute TRDA market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing TRDA market cap history over the course of time is important for investors
interested in comparing TRDA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of TRDA versus a peer is one thing; comparing
TRDA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like TRDA can fluctuate over the course of history.
With this page we aim to empower investors researching TRDA by allowing them to research the TRDA market cap history. |
Free TRDA Email Alerts:
Video: The Importance of Market Cap
